Vivek Subbiah: Pleased to share my thoughts on Lurbinecredin data in small cell lung cancer

Vivek Subbiah shared a post on LinkedIn:

“Pleased to share my thoughts on Lurbinecredin data in small cell lung cancer.

Lurbinectedin is a marine-derived drug that inhibits transcription, a process that is frequently dysregulated in small cell lung cancer.

In March 2023, Switzerland granted approval for lurbinectedin in patients with SCLC experiencing disease progression. The approval specifically applied to patients with a CTFI of at least 30 days without CNS metastases. ”

Read further
Source: Vivek Subbiah/LinkedIn

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.